TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25864745
Drug: FS plus
Normalized name: MILK THISTLE 6 [hp_X] in 1 mL / HELIANTHEMUM CANADENSE 6 [hp_X] in 1 mL / SOLANUM DULCAMARA TOP 6 [hp_X] in 1 mL / GALIUM APARINE 6 [hp_X] in 1 mL / MAGNESIUM CHLORIDE 6 [hp_X] in 1 mL / SODIUM SULFATE 6 [hp_X] in 1 mL / VISCUM ALBUM FRUITING TOP 6 [hp_X] in 1 mL / HYDROCHLORIC ACID 6 [hp_X] in 1 mL / ESTRONE 8 [hp_X] in 1 mL / SODIUM CHLORIDE 10 [hp_X] in 1 mL / AILANTHUS ALTISSIMA FLOWERING TWIG 12 [hp_X] in 1 mL / BARIUM CHLORIDE DIHYDRATE 12 [hp_X] in 1 mL / CADMIUM 12 [hp_X] in 1 mL / CEANOTHUS AMERICANUS LEAF 12 [hp_X] in 1 mL / ANAMIRTA COCCULUS SEED 12 [hp_X] in 1 mL / IRIDIUM 12 [hp_X] in 1 mL / THUJA OCCIDENTALIS LEAFY TWIG 12 [hp_X] in 1 mL / CINCHONA OFFICINALIS BARK 12 [hp_X] in 1 mL / OYSTER SHELL CALCIUM CARBONATE, CRUDE 12 [hp_X] in 1 mL / CROTALUS DURISSUS TERRIFICUS VENOM 16 [hp_X] in 1 mL ORAL LIQUID [EBV/CFS Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS plus thyroid hormones
Study: 17895439
Drug: Community occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community occupational therapy (10 sessions over 5 weeks)
Study: 8874912
Drug: Ondansetron 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 0.06 mg.kg‐1 i.v.
Study: 8874912
Drug: Prochlorperazine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine 0.1 mg.kg‐1 i.v.
Study: 8874912
Drug: Placebo (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (isotonic saline) 0.02 ml.kg‐1 i.v.
Study: 26739975
Drug: 250 μ/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μ/kg intravenous ketamine
Study: 2312764
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg intravenous infusion
Study: 9052581
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration
Study: 31359099
Drug: Medication review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication review using STOPP/START criteria
Study: 23444965
Drug: Emulin/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emulin/metformin
Study: 23444965
Drug: placebo/no medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/no medication
Study: 31326727
Drug: placebo/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/metformin
Study: 21211642
Drug: Timothy grass
Normalized name: Timothy grass
DrugBank: Phleum pratense top (DB14179)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timothy grass AIT treatment (2,800 bioequivalent allergen units, approximately 15 μg of Phl p 5)
Study: 19758607
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of progestin and endometrial protective doses of estradiol, administered immediately after delivery and continuously during the first three months post-partum.
Study: 15508056
Drug: Levovist (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levovist (1 g i.v. injection)
Study: 11336120
Drug: Financial incentives,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentives, tracking prescriptions, prompting positive feedback from patients, adopting anti-tobacco counseling models
Study: 7928859
Drug: 10% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbohydrate (CHO) drink (CI) at 500 ml/h
Study: 11527140
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg/day
Study: 11527140
Drug: Mepindolol 10
Normalized name: mepindolol
DrugBank: Mepindolol (DB13530)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepindolol 10 mg/day
Study: 17453746
Drug: All beta-blockers
Normalized name: all-trans-beta-Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beta-blockers
Study: 7743684
Drug: Flecainide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (200 mg/day)
Study: 23965491
Drug: Alogliptin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin treatment group (172 patients)
Study: 23965491
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment group (169 patients)
Study: 18487568
Drug: Palifermin 60
Normalized name: palifermin
DrugBank: Palifermin (DB00039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palifermin 60 microg/kg once weekly for 10 doses
Study: 21360490
Drug: Tocilizumab 8
Normalized name: tocilizumab 80 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 8 mg/kg plus MTX
Study: 21360490
Drug: Tocilizumab 4
Normalized name: tocilizumab 400 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab 4 mg/kg plus MTX
Study: 8810961
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression device (SCD)
Study: 1349259
Drug: Azelastine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (2 mg, single oral dose)
Study: 4047540
Drug: 100-g glucose
Normalized name: glucose 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-g glucose polymer tolerance test
Study: 18469243
Drug: Low-zinc meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-zinc meals (4 mg Zn/d) with zinc tracer
Study: 18469243
Drug: Adequate-zinc meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate-zinc meals (11 mg Zn/d) with zinc stable isotope tracer
Study: 16540792
Drug: Conventional enteric-coated
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional enteric-coated enzyme (EC-PE) capsule
Study: 15354759
Drug: Pneumonic mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumonic mechanical ventilation associated with sulphureous water aerosol inhalation
Study: 15354759
Drug: Mechanical pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical pulmonary ventilation associated with sulphureous water aerosol inhalation medicated with flunisolide
Study: 11006200
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 microg every 3 h up to five doses
Study: 11006200
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol 200 microg every 3 h up to five doses
Study: 9060013
Drug: Epinephrine or
Normalized name: epinephrine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine or phenylephrine (30 micrograms in 3 ml)
Study: 27885499
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg
Study: 3034038
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg and 10 mg
Study: 16494640
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg
Study: 23172333
Drug: Metallic implants
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metallic implants (Group I)
Study: 23172333
Drug: Biodegradable implants
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable implants (Group II)
Study: 18575629
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (5 intramuscular injections at monthly intervals)
Study: 18575629
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (high antibody levels)
Study: 18575629
Drug: Nicotine vaccine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine vaccine (high antibody response)
Study: 3500032
Drug: Normovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normovolemic hemodilution (15 mg/kg body-weight) with intra-operative autotransfusion (Cell-Saver) in group I
Study: 22846446
Drug: Obituary specifying
Normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obituary specifying drug overdose as the cause of death
Study: 21771948
Drug: Pediatric Constraint‐Induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric Constraint‐Induced Movement therapy
Study: 19917453
Drug: Low saturated
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low saturated fat (LSF) diet with 25 g of soy protein and 15 g of soluble fiber daily for 2 months
Study: 16060253
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of carotid artery stenting (CAS) and carotid endarterectomy (CEA)
Study: 12779247
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice a day for 5 weeks
Study: 2646995
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray (BDP‐AQ) 42 micrograms/spray, 1 spray in each nostril twice daily
Study: 23404353
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (Bioclavid) for 100 days
Study: 18205945
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus amodiaquine as a single daily intake
Study: 18205945
Drug: Artesunate plus
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate plus amodiaquine as two daily intakes
Study: 11145798
Drug: MFMA spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFMA spinal manipulative therapy (SMT)
Study: 28143430
Drug: Acetaminophen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (10 mg/kg)
Study: 6719656
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon intravenously
Study: 23645886
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 40 μg/day
Study: 27188979
Drug: Bupropion (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (150 mg/day)
Study: 11728983
Drug: High CRP
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High CRP levels (> 16.8 mg/L) in dialysis patients
Study: 7548920
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g lactulose
Study: 16507193
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no test drug)
Study: 2404514
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream applied once daily for 12 weeks
Study: 2404514
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied once daily for 12 weeks
Study: 26643326
Drug: Paritaprevir (NS3/4A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paritaprevir (NS3/4A inhibitor boosted with ritonavir) and Ombitasvir (NS5A inhibitor)
Study: 23467861
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 0.9% saline solution (control)
Study: 16831654
Drug: Standard metal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metal mini-fragment implants
Study: 12796070
Drug: Fondaparinux 2.5
Normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 2.5 mg once-daily subcutaneous injection for 19 to 23 days
Study: 10229588
Drug: Intratympanic gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratympanic gentamicin infusion (26.7 mg/mL, 0.2 to 0.3 mL)
Study: 8911453
Drug: Metronidazole at
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole at a concentration of 5 mg/ml
Study: 26817469
Drug: COX inhibitor
Normalized name: COX inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX inhibitor (acetaminophen, 4 gram/day)
Study: 12162469
Drug: Enalapril (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (low dose: 0.625 or 1.25 mg, middle dose: 2.5 or 5 mg, high dose: 20 or 40 mg)
Study: 12162469
Drug: Enalapril (middle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (middle and high dose)
Study: 7750159
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg DHC
Study: 2943994
Drug: Albuterol (beta-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (beta-2 adrenergic agent)
Study: 2943994
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (anticholinergic agent)
Study: 2943994
Drug: Albuterol followed
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol followed by Ipratropium bromide
Study: 2943994
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide followed by Albuterol
Study: 31944869
Drug: VAULT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAULT treatment (3 target words/90 doses per word per session)
Study: 31944869
Drug: VAULT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAULT treatment (6 target words/45 doses per word per session)
Study: 2738457
Drug: No-treatment condition
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment condition
Study: 2468927
Drug: Atenolol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (1, 1, 2, and 4 mg)
Study: 2935349
Drug: Celiprolol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (1, 1, 2, and 4 mg)
Study: 17050869
Drug: Cisplatin 75
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 75 mg/m2 plus pemetrexed 500 mg/m2
Study: 17050869
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 5 plus pemetrexed 500 mg/m2
Study: 7818061
Drug: Lignocaine-propofol combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine-propofol combination
Study: 7818061
Drug: Metoclopramide-propofol combination
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide-propofol combination
Study: 28251755
Drug: Several biomarkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several biomarkers (individually and in combination)
Study: 21193287
Drug: Modified Manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Manual Edema Mobilization (MEM) treatment
Study: 21193287
Drug: Traditional edema
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional edema treatment
Study: 14709456
Drug: Midazolam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (30 ng.mL(‐1) target effect site concentration)
Study: 9514561
Drug: Capsaicin administered
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin administered subcutaneously in the right forehead to evoke a burning painful sensation.
Study: 9514561
Drug: Capsaicin administration
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin administration
Study: 2181031
Drug: Vaccine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (50 micrograms) administered intramuscularly at weeks 0, 4, and 22
Study: 2181031
Drug: Vaccine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (50 micrograms)
Study: 31915983
Drug: Immunosuppressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive treatment (number of immunosuppressants)
Study: 31166571
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus oral antidepressant
Study: 31109201
Drug: Antidepressant plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant plus placebo nasal spray
Study: 27599663
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab every week
Study: 23866917
Drug: Sequential stage-matched
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential stage-matched intervention targeting procurement and consumption of fruits, vegetables, salt, sugar, and oil; delivered over 1 year with strategies at 0, 6, and 12 months, including counselling sessions, telephonic reminders, and home visits.
Study: 11332061
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% with saline (3 mg.kg‐1)
Study: 11332061
Drug: Lidocaine 0.5%
Normalized name: LIDOCAINE 0.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.5% with clonidine (150 micrograms) (3 mg.kg‐1)
Study: 9202914
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Study: 9202914
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of anaesthetic solution (0.5% bupivacaine with adrenaline 1:200,000 and 2% lignocaine)
Study: 7881027
Drug: Atropine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1 mg/day)
Study: 335279
Drug: Cimetidine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (1000 mg/day)
Study: 20595145
Drug: budesonide/formoterol 160/4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide/formoterol 160/4.5 μg, 2 × 2 inhalations b.i.d.
Study: 17874255
Drug: Armodafinil (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil (150 or 250 mg)
Study: 12791115
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg.kg‐1
Study: 12791115
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg.kg‐1
Study: 12791115
Drug: Ketamine 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.15 mg.kg‐1 plus magnesium sulphate 30 mg.kg‐1
Study: 1600053
Drug: Pantoprazole 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 60 mg
Study: 30782680
Drug: Corticosteroid (betamethasone)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid (betamethasone) with hyaluronic acid (HA) injection
Study: 30782680
Drug: Corticosteroid (betamethasone)
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid (betamethasone) injection
Study: 27577510
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (320 mg I/mL iodixanol)
Study: 3292601
Drug: Cholestyramine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine (8 g twice daily)
Study: 3270328
Drug: Cocaine infusion
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusion (IV)
Study: 26619355
Drug: Prophylactic placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic placebo cream
Study: 24919692
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein supplementation (20.7 g of protein, 9.3 g of carbohydrate, and 3.0 g of fat) twice daily
Study: 22624502
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg every 12 hours for 10 days
Study: 22624502
Drug: Danoprevir 100
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir 100 mg alone
Study: 1602793
Drug: Modified LSA2L2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified LSA2L2 therapy (with or without intensified intrathecal chemotherapy and radiotherapy)
Study: 24205943
Drug: Saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saxagliptin 5 mg once daily
Study: 26923491
Drug: Daily review
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily review of antimicrobial use
Study: 25344703
Drug: Group reminiscence
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group reminiscence therapy (6 sessions)
Study: 22828921
Drug: G. glauca
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. glauca herbal medicinal product
Study: 20225073
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of femoral, lateral femoral cutaneous, and sciatic nerve blocks with obturator nerve block
Study: 1375648
Drug: Topical capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical capsaicin 0.075% applied 4 times daily for 4 weeks
Study: 21617554
Drug: Adverse events
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse events in combination group
Study: 18422727
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg p277
Study: 18422727
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg p277
Study: 2841053
Drug: atenolol 50-100
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 50-100 mg/day
Study: 15017529
Drug: Angiotensin-Converting Enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-Converting Enzyme Inhibitors (ACE inhibitors)
Study: 31760711
Drug: Angiotensin Receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin Receptor Blockers (ARBs)
Study: 15017529
Drug: Combination antihypertensive
Normalized name: ANTIHYPERTENSIVE COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination antihypertensive therapy including ACE inhibitors or ARBs
Study: 9322717
Drug: Antiseptic or
Normalized name: Antiseptic Oral Rinse
DrugBank: Cetylpyridinium (DB11073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiseptic or antibiotic lavage
Study: 2719236
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural morphine